Area of research
Oncology · Cancer Research
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Breast Cancer Treatment Studies, Melanoma and MAPK Pathways, and Breast Lesions and Carcinomas.
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study
Landscape of mutations in early stage primary cutaneous melanoma: An <scp>InterMEL</scp> study
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience
Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis
Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
A risk prediction model for the development of subsequent primary melanoma in a population‐based cohort
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
Association Between<i>NRAS</i>and<i>BRAF</i>Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma
Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma